Navigation Links
The Launch and Uptake of More Than 20 Novel Drugs Over The Next 10 Years Will Drive $12.5 Billion Growth in the Type 2 Diabetes Market
Date:5/20/2009

Commercial Potential of Market is Reflected in Burgeoning Pipeline of More than 400 Drugs in Development, According to a New Report from Decision Resources

WALTHAM, Mass., May 20 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the launch and uptake of more than 20 novel antidiabetic drugs over the next 10 years will drive the type 2 diabetes market to increase by $12.5 billion in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Type 2 Diabetes finds that both novel and existing DPP-IV inhibitors and GLP-1 analogues - such as Merck's Januvia, Bristol-Myers Squibb/AstraZeneca's Onglyza and Amylin/Eli Lilly/Alkermes' Byetta LAR - hold the greatest promise for type 2 diabetes because these drug classes improve upon key areas of safety and efficacy. DPP-IV inhibitors have a very low risk of hypoglycemia and an excellent tolerability profile, making them suitable for widespread use. GLP-1 analogues, which combine superior glucose-lowering and weight loss capabilities compared with other drug classes, are particularly useful treatments for the significant proportion of type 2 diabetics who are obese.

"The commercial potential for drugs with demonstrated disease-modifying capabilities and long-term efficacy is reflected in the burgeoning pipeline for type 2 diabetes, which currently has more than 400 drugs in active development," said Decision Resources Analyst Christine Helliwell, Ph.D. "However, with a greater regulatory burden in the United States and an increasingly crowded market, the barriers for success are higher than ever before."

The report also finds that generic competition will weaken the market share of the PPAR-gamma agonists--Takeda's Actos and GlaxoSmithKline's Avandia--reducing sales of these agents by more than 50 percent over the 2008 to 2018 study period. The PPAR-gamma agonists, along with metformin (Bristol-Myers Squibb/Merck Sorono's Glucophage/Glucophage XR, Biovail/Depomed's Glumetza, Watson's Fortamet, generics) and the sulfonylureas, both of which are already generically available, are the most commonly prescribed first-, second-, and third-line oral therapies. Generic availability of all three drug classes will provide formidable competition for new, more-expensive drugs in the market.

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at http://www.DecisionResourcesInc.com.

    Decision Resources               Decision Resources, Inc.
    Christopher Comfort              Elizabeth Marshall
    781-296-2597                     781-296-2563
    ccomfort@dresources.com          emarshall@dresources.com

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy
2. USMLE Galaxy, LLC Launches Live and Cost Effective USMLE Review Courses and Practice Sessions Right on Your Desktop through its Subsidiary CcsWorkshop.com
3. Haverford Wellness Center Launches Web Site Devoted to Accurate Diagnosis and Proper Treatment to Cure Lyme Disease
4. American College of Physicians Chooses iPublishCentral to Launch its e-Book Strategy
5. Gold Star Resources Corp. Launches Humanitarian Society to Aid Liberian People
6. Photos: Will Ferrell Sunscreen to Launch Just in Time for Summer
7. Booty Camp(R) Potty Training Program as Featured in People Magazine is Launched on DVD
8. IBD Patient Launches iPhone Application to Help Doctors Treat Crohns and Ulcerative Colitis
9. Photos: USANA Launches National Rev3 Geocaching Challenge
10. ACORN CRO Launches STAR (Site Tracking and Recruitment)
11. StreetWise HSA(SM) Launched Nationally: First Low-Cost, Customizable Platform for Employee HSA Education
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... ... February 10, 2016 , ... Ongoing news of the ravages of traumatic ... to conduct a survey that takes a closer look at cases of TBI being ... and causes of TBI among the aging population, and identifies the challenges associated with ...
(Date:2/10/2016)... ... February 10, 2016 , ... Armune BioScience signed ... their network of laboratory service centers across the country. Launched in April of 2015, ... the detection of prostate cancer. Apifiny order volume exceeded 3,000 tests in 2015. Primary ...
(Date:2/10/2016)... ... February 10, 2016 , ... The Club at ... the prestigious Distinguished Emerald Club of the World award, as determined by the ... of the most respected trade publications serving private clubs. , “We’d like to ...
(Date:2/10/2016)... ... 10, 2016 , ... Workrite Ergonomics, who is celebrating their 25th year of ... to being an internationally recognized leader in their industry. , "We are very proud ... President of Workrite. “Workrite recognized the importance of good ergonomics before most of ...
(Date:2/10/2016)... ... February 09, 2016 , ... Ross A. ... are delighted to welcome a new addition to their growing practice. Beginning this ... as a nurse practitioner performing cosmetic procedures including injectables, fillers and ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)...  Visage Imaging Inc. ("Visage"), a wholly owned ... that the American College of Radiology (ACR) and ... Visage 7 Enterprise Imaging Platform as the new ... SIMulation (SIM). SIM is the assessment component of ... multi-faceted and fully-integrated online assessment, education and remediation ...
(Date:2/10/2016)... -- CERS ), Medivation, Inc. (NASDAQ: MDVN ... Therapeutics, Inc. (NASDAQ: CLDX ). --> CERS ... (NASDAQ: ADMS ) and Celldex Therapeutics, Inc. (NASDAQ: ... become vitally important in the development of targeted treatment therapies ... which are defined as those intended for the safe and ...
(Date:2/10/2016)... Israel , February 10, 2016 /PRNewswire/ ... leader in the field of cartilage repair, announces the ... 5, 2016. The $15 million investment was led by ... pharmaceutical manufacturer, and was joined by existing Regentis investors ... and both the Technion Research & Development Foundation and ...
Breaking Medicine Technology: